Story
AI Drug Developer Iambic Therapeutics, Backed by Nvidia, Files for US IPO
Summary
The clinical-stage biotech company plans to list on the Nasdaq under the ticker 'IAM' to fund the advancement of its pipeline of AI-discovered cancer therapies.
Iambic Therapeutics, a clinical-stage biotechnology company that uses artificial intelligence to develop cancer treatments, has filed for an initial public offering in the U.S. The San Diego-based firm, which counts chipmaker Nvidia Corp. as a shareholder, plans to list on the Nasdaq Global Select Market under the ticker symbol IAM.
Use of Proceeds and Offering Details
According to a regulatory filing submitted on Monday to the U.S. Securities and Exchange Commission, Iambic intends to use the net proceeds from the IPO to advance its pipeline of three early-stage oncology drugs. The company did not disclose the number of shares it plans to offer or the target price range for the offering.
The offering is being underwritten by a syndicate of major banks, including J.P. Morgan, Jefferies, BofA Securities, and Citigroup. The underwriters have been granted a 30-day option to purchase additional shares.
AI-Powered Oncology Pipeline
Iambic's most advanced candidate is IAM1363, an oral small molecule inhibitor designed to target human epidermal growth factor receptor 2 (HER2). The company reported that as of September 2026, the drug is in an ongoing Phase 1/1b clinical trial for patients with advanced HER2-altered solid tumors.
AdThe company is also preparing to advance two other programs, with plans to file Investigational New Drug (IND) applications for both in the fourth quarter of 2026:
- IAM217: A brain-penetrant inhibitor targeting KIF18A, with potential applications in ovarian and triple-negative breast cancer.
- IAM-C1: A selective dual inhibitor of cyclin-dependent kinases 2 and 4 (CDK2/4).
High-Profile Financial Backing
Prior to its IPO filing, Iambic Therapeutics has attracted significant venture capital investment. The company has raised approximately $461.8 million in capital through September 18, 2026.
Its roster of investors includes prominent firms such as Catalio, Nexus Ventures, Q Healthcare Holding, Coatue Ventures, and AI industry leader Nvidia. This backing highlights investor confidence in the company's AI-driven approach to drug discovery ahead of its public market debut.
Read next
More on Stocks
AnaptysBio Shares Rise After Q2 Revenue Beats Analyst Estimates
AnaptysBio Inc. (ANAB) saw its stock climb in after-hours trading following the release of second-quarter financial results that significantly surpassed revenue expectations, driven by its drug collaboration pipeline.
U.S. Stock Futures Rise, Buoyed by AI-Led Tech Rally and Lower Oil Prices
U.S. equity futures advanced in evening trading, building on a session where a surge in AI-related stocks like Meta and AMD pushed the Nasdaq to a record high, while falling oil prices also improved investor sentiment.
Binance Under U.S. Investigation for Potential Iran Sanctions Violations, Bloomberg Reports
The world's largest cryptocurrency exchange is reportedly being investigated by federal prosecutors over its compliance with U.S. sanctions on Iran, adding to its history of regulatory challenges.
LG Electronics Shares Jump 6% on Nvidia Qualification for AI Data Center Cooling Unit
Shares of LG Electronics surged after Nvidia qualified its 2.6-megawatt liquid cooling unit for AI data centers, a key validation that strengthens the company's position in the critical AI infrastructure market.